Table 1.

Summary of the role of pro-resolution lipid mediators in animal models of infectious disease

Infection	Model	Finding	Reference
Lipoxins
Influenza A	Mouse	Down-regulation of SOCS2 (required for lipoxin activity) associated with greater virulence	12
Respiratory syncytial virus	Mouse	5-lipoxygenase deficiency (required for lipoxin production) associated with greater lung pathology	15
Mycobacterium tuberculosis	Mouse	Lipoxin contributes to mortality and mycobacterial load	19
Toxoplasma gondii	Mouse	Lipoxin reduces mortality but increases parasite load	21–22
Trypanosoma cruzi	Mouse	15-epi-lipoxin A4 reduces parasitaemia and increases survival	23
Plasmodium berghei-ANKA	Mouse	15-epi-lipoxin A4 increases survival	24
Periodontitis (Porphyromonas gingivalis)	Rabbit	Lipoxin reduces leucocyte infiltration and bone destruction	25
Resolvins
Sepsis	Mouse	Resolvin reduces mortality	29
Escherichia coli peritonitis	Mouse	Resolvin reduces mortality and enhanced the antimicrobial effect of ciprofloxacin	30
Staphylococcus aureus skin infection	Mouse	Resolvin enhances the antimicrobial effect of vancomycin	30
Burn-related sepsis	Rat	Resolvin reduces mortality	31
E. coli pneumonia	Mouse	Resolvin reduces histological severity of pneumonia and mortality	32–34
E. coli peritonitis-associated acute lung injury	Mouse	Resolvin reduces mortality	34
Ocular herpes simplex virus	Mouse	Resolvin reduces lesion severity	36
Protectins
Influenza A	Mouse	Protectin reduces viral replication in vitro and increases survival in vivo.	37